RU2017132516A - Композиции для применения в лечении опухолей, резистентных к химиотерапии - Google Patents
Композиции для применения в лечении опухолей, резистентных к химиотерапии Download PDFInfo
- Publication number
- RU2017132516A RU2017132516A RU2017132516A RU2017132516A RU2017132516A RU 2017132516 A RU2017132516 A RU 2017132516A RU 2017132516 A RU2017132516 A RU 2017132516A RU 2017132516 A RU2017132516 A RU 2017132516A RU 2017132516 A RU2017132516 A RU 2017132516A
- Authority
- RU
- Russia
- Prior art keywords
- composition
- treatment
- paragraphs
- alternatively
- group
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/29—Berberidaceae (Barberry family), e.g. barberry, cohosh or mayapple
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/66—Papaveraceae (Poppy family), e.g. bloodroot
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Claims (22)
1. Композиция для применения в лечении химиорезистентных опухолей, содержащая смесь, содержащую или, альтернативно, состоящую из:
(1) по меньшей мере одного флавоноида, выбранного из группы, включающей или, альтернативно, состоящей из рутина, оксерутина, диосмина, троксерутина и гесперидина; и
(2) по меньшей мере одного химиотерапевтического агента.
2. Композиция для применения по п. 1, где указанный по меньшей мере один химиотерапевтический агент выбран из циклофосфамида, 5-фторурацила, метотрексата, комплексов платины, таксанов, доксорубицина, эпирубицина и митоксантрона; предпочтительно, он представляет собой циклофосфамид и/или метотрексат.
3. Композиция для применения по любому из пп. 1-2, где компонент (1) представляет собой рутин и компонент (2) представляет собой циклофосфамид и/или метотрексат.
4. Композиция для применения по п. 1, где указанная смесь дополнительно содержит по меньшей мере одно соединение, выбранное из группы, включающей или, альтернативно, состоящей из арктигенина, арктиина, берберина, бербамина, сангвинарина, хелеритрина и Harpagophytum procumbens как таковых или в форме растительных экстрактов, содержащих указанные соединения.
5. Композиция для применения по любому из пп. 1-4, где указанная смесь содержит по меньшей мере один экстракт, происходящий из:
а) растения, принадлежащего к семейству Asteraceae, выбранного из группы, включающей Arctium lappa, Cnicus benedictus и Saussurea medusa;
б) растения, принадлежащего к семейству Berberidaceae, выбранного из группы, включающей Berberis vulgaris, Berberis aristata и Mahonia aquifolium;
в) растения, принадлежащего к семейству Papaveraceae, выбранного из группы, включающей Eschscholzia californica, Macleaya cordata или Bocconia frutescens;
г) Harpagophytum procumbens (чертов коготь).
6. Композиция для применения по любому из пп. 1-5, где указанная смесь дополнительно содержит по меньшей мере один экстракт, происходящий из:
а) Arctium lappa;
б) Berberis vulgaris;
в) Eschscholzia californica.
7. Композиция для применения по любому из пп. 1-6, где указанная смесь содержит компоненты и/или вещества в микронизированной форме.
8. Композиция по любому из пп. 1-7 для применения в качестве адъюванта с химиотерапевтическими агентами для лечения опухолей, резистентных к химиотерапии, то есть для повышения эффективности химиотерапевтического лечения, применяемого в медицине и ветеринарии для лечения опухолей, предпочтительно солидных опухолей, в частности в случае резистентности к химиотерапевтическим агентам, применяемым в настоящее время.
9. Композиция для применения в лечении опухолей и для предупреждения/подавления химиорезистентности к антибластическим лекарственным средствам и/или радиорезистентности к лучевой терапии, содержащая смесь, содержащую или, альтернативно, состоящую из:
(1) по меньшей мере одного флавоноида, выбранного из группы, включающей или, альтернативно, состоящей из рутина, оксерутина, диосмина, троксерутина и гесперидина;
(2) метотрексата и/или циклофосфамида; и возможно
(4) по меньшей мере одного соединения, выбранного из группы, включающей или, альтернативно, состоящей из арктигенина, арктиина, берберина, бербамина, сангвинарина, хелеритрина и Harpagophytum procumbens (чертов коготь, который ингибирует синтез PGE2), самих по себе или в форме растительных экстрактов, содержащих указанные соединения.
10. Композиция по любому из пп. 1-9 для применения в лечении резистентных солидных опухолей и рака молочной железы у женщин.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ITMI20150332 | 2015-03-05 | ||
IT102015902336226 | 2015-03-05 | ||
PCT/IB2016/051216 WO2016139625A1 (en) | 2015-03-05 | 2016-03-04 | Compositions for use in the treatment of tumors resistant to chemotherapy |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2017132516A true RU2017132516A (ru) | 2019-04-08 |
RU2017132516A3 RU2017132516A3 (ru) | 2019-09-02 |
Family
ID=52781183
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2017132516A RU2017132516A (ru) | 2015-03-05 | 2016-03-04 | Композиции для применения в лечении опухолей, резистентных к химиотерапии |
Country Status (9)
Country | Link |
---|---|
US (1) | US11096975B2 (ru) |
EP (1) | EP3265071A1 (ru) |
JP (1) | JP2018507237A (ru) |
KR (1) | KR20170125045A (ru) |
CN (1) | CN107530386A (ru) |
BR (1) | BR112017018516A2 (ru) |
CA (1) | CA2977910A1 (ru) |
RU (1) | RU2017132516A (ru) |
WO (1) | WO2016139625A1 (ru) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6837960B2 (ja) | 2014-07-17 | 2021-03-03 | プロバイオティカル・ソシエタ・ペル・アチオニProbiotical S.P.A. | 化学療法に耐性である腫瘍の処置において用いるための、メラトニンおよびフラボノイド類を含む組成物 |
CN112618569A (zh) * | 2020-12-31 | 2021-04-09 | 深圳市众循精准医学研究院 | 一种用于治疗尿路上皮癌的药物 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU5160201A (en) | 2000-04-17 | 2001-10-30 | Hauser Inc | Compositions comprising natural agents for treatment of cancer |
US6426351B1 (en) | 2000-08-11 | 2002-07-30 | Dana-Farber Cancer, Inc. | Chelerythrine-based therapies for cancer |
JP2005529123A (ja) * | 2002-04-24 | 2005-09-29 | リサーチ ディベロップメント ファンデーション | 核転写調節因子NF−κB抑制剤と抗腫瘍薬の相乗効果 |
CN1470513A (zh) | 2003-07-14 | 2004-01-28 | 靳玉群 | 一种具有抗癌活性的总生物碱及其制剂 |
CN1243103C (zh) | 2004-02-26 | 2006-02-22 | 广州中医药大学 | 一种制备抗病毒与抗肿瘤天然药物牛蒡子苷元的方法 |
WO2006032380A1 (en) | 2004-09-20 | 2006-03-30 | Nowicky Wassili | Quaternary alkaloid derivatives of chelidonium majus l |
EP1656939A1 (en) | 2004-11-10 | 2006-05-17 | Pooger Properties Limited | Use of melatonin in the manufacture of a medicament for treating cancer |
CN100432092C (zh) | 2006-08-24 | 2008-11-12 | 郑州大学 | 芦丁铂的合成 |
EP1967193A1 (en) * | 2007-03-05 | 2008-09-10 | Vrije Universiteit Medisch Centrum (VUMC) | Enhancement of anticancer therapy by flavonoids |
NZ555163A (en) * | 2007-05-14 | 2010-05-28 | Fonterra Co Operative Group | Methods of immune or hematological enhancement, inhibiting tumour formation or growth, and treating or preventing cancer, cancer symptoms, or the symptoms of cancer treatments |
EP2119434A1 (en) * | 2008-05-13 | 2009-11-18 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Use of heterosidic flavonoid derivatives for therapy of stem cell cancers |
WO2010001391A1 (en) | 2008-06-30 | 2010-01-07 | Oron Zachar | Dermal application of vasoconstrictors |
WO2012141575A1 (en) | 2011-04-14 | 2012-10-18 | N.V.Nutricia | Combination of epa, dpa and/or dha with a chemotherapeutic agent |
US20130045179A1 (en) * | 2011-08-15 | 2013-02-21 | Mihai Ciustea | Combination therapy and methods for treatment and prevention of hyperproliferative diseases |
US9211298B2 (en) * | 2012-11-16 | 2015-12-15 | Song Gao | Compositions containing enriched natural crocin and/or crocetin, and their therapeutic or nutraceutical uses |
BR112015024537B1 (pt) | 2013-04-12 | 2022-09-06 | Ned Biosystems, Inc | Uso de (i) ciclofosfamida, (ii) metformina, (iii) curcumina, (iv) melatonina, (v) naltrexona, (vi) ácido alfa lipoico e (vii) genisteína e combinação no tratamento de câncer |
ITMI20131495A1 (it) | 2013-09-10 | 2015-03-11 | Ce R C Ar Di Paolo Maestri | Composizioni utili per il trattamento di tumori resistenti alla chemioterapia |
JP6837960B2 (ja) * | 2014-07-17 | 2021-03-03 | プロバイオティカル・ソシエタ・ペル・アチオニProbiotical S.P.A. | 化学療法に耐性である腫瘍の処置において用いるための、メラトニンおよびフラボノイド類を含む組成物 |
-
2016
- 2016-03-04 WO PCT/IB2016/051216 patent/WO2016139625A1/en active Application Filing
- 2016-03-04 CN CN201680013028.6A patent/CN107530386A/zh active Pending
- 2016-03-04 JP JP2017546598A patent/JP2018507237A/ja active Pending
- 2016-03-04 EP EP16718006.6A patent/EP3265071A1/en not_active Withdrawn
- 2016-03-04 BR BR112017018516A patent/BR112017018516A2/pt not_active IP Right Cessation
- 2016-03-04 KR KR1020177025886A patent/KR20170125045A/ko unknown
- 2016-03-04 RU RU2017132516A patent/RU2017132516A/ru unknown
- 2016-03-04 CA CA2977910A patent/CA2977910A1/en not_active Abandoned
- 2016-03-04 US US15/555,920 patent/US11096975B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
CA2977910A1 (en) | 2016-09-09 |
CN107530386A (zh) | 2018-01-02 |
US11096975B2 (en) | 2021-08-24 |
KR20170125045A (ko) | 2017-11-13 |
RU2017132516A3 (ru) | 2019-09-02 |
BR112017018516A2 (pt) | 2018-04-17 |
JP2018507237A (ja) | 2018-03-15 |
WO2016139625A1 (en) | 2016-09-09 |
EP3265071A1 (en) | 2018-01-10 |
US20180064774A1 (en) | 2018-03-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Wagner | Synergy research: approaching a new generation of phytopharmaceuticals | |
HRP20231537T1 (hr) | Derivati tetrahidronaftalena i tetrahidroizokinolina kao degradatori estrogenskih receptora | |
JP2020100659A5 (ru) | ||
JP2021169479A5 (ru) | ||
RU2016110352A (ru) | Композиции, содержащие рутин, полезные для лечения опухолей, резистентных к химиотерапии | |
RU2017102705A (ru) | Композиции, содержащие мелатонин и флавоноиды, для использования в лечении опухолей, резистентных к химиотерапии | |
Popovic-Milenkovic et al. | Antioxidant and anxiolytic activities of Crataegus nigra Wald. et Kit. berries | |
RU2017132516A (ru) | Композиции для применения в лечении опухолей, резистентных к химиотерапии | |
AR075039A1 (es) | Formulacion farmaceutica o alimentaria de liberacion controlada y procedimiento para su preparacion | |
Allemailem | Antimicrobial potential of naturally occurring bioactive secondary metabolites | |
JP2018510195A5 (ru) | ||
Banik et al. | Heterocyclic Anticancer Agents | |
Jordão et al. | Trypanocidal activity of chemical constituents from Lychnophora salicifolia Mart | |
Awolola et al. | Identification of secondary metabolites and resistance modifying activity of Ficus bizanae leaf, stem bark and fruit extracts | |
AR037543A1 (es) | Metodo para la terapia del cancer y composicion farmaceutica | |
CN107029122B8 (zh) | 一种治疗高血压的药物组合物及其制备方法、制剂与应用 | |
RU2021103531A (ru) | Фармацевтическая композиция в виде жевательной таблетки диосмина или флавоноидной фракции | |
Anyanwu | Trypanocidal potential of Carrisa edulis in male wistar rats infected with T. congolense. | |
Rao et al. | Importance of Plant Secondary Metabolites in Modern Therapy | |
LIMA et al. | Anthelminthic evaluation of extracts and natural compounds from Pterogyne nitens (Fabaceae) against nematodes of veterinary interest. | |
Malviya et al. | Comparative evaluation and anthelmintic potential of roots and leaves extracts of Lantana camara linn | |
Pirvu et al. | Plant compounds synergistic activity benefits on human health | |
Maurya et al. | Pi3k Inhibitors | |
RU2019109965A (ru) | Лекарственное средство, эффективное для лимфогенного способа введения лекарственного средства | |
ITFI20000240A1 (it) | Estratti ottenuti da asteraceae contenenti miscele di terpenoidi e composti fenolici,loro preparazione ed uso come fitofarmaci sistemici ant |